Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Treasury Shares (2023 - 2025)

InMed Pharmaceuticals (INM) has 4 years of Treasury Shares data on record, last reported at $3.7 million in Q4 2025.

  • For Q4 2025, Treasury Shares rose 7826.09% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, up 7826.09%, while the annual FY2025 figure was $4.5 million, 734.35% up from the prior year.
  • Treasury Shares reached $3.7 million in Q4 2025 per INM's latest filing, down from $3.9 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $13.2 million in Q1 2024 and bottomed at $42096.0 in Q1 2025.
  • Average Treasury Shares over 4 years is $2.5 million, with a median of $544280.0 recorded in 2024.
  • The widest YoY moves for Treasury Shares: up 7826.09% in 2025, down 99.68% in 2025.
  • A 4-year view of Treasury Shares shows it stood at $505128.0 in 2022, then rose by 10.72% to $559267.0 in 2023, then plummeted by 91.56% to $47176.0 in 2024, then surged by 7826.09% to $3.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $3.7 million in Q4 2025, $3.9 million in Q3 2025, and $4.5 million in Q2 2025.